TY - JOUR
T1 - Untreated cervical intraepithelial neoplasia grade 2 and subsequent risk of cervical cancer
T2 - Population based cohort study
AU - Lycke, Kathrine Dyhr
AU - Kahlert, Johnny
AU - Petersen, Lone Kjeld
AU - Damgaard, Rikke Kamp
AU - Cheung, Li C.
AU - Gravitt, Patti E.
AU - Hammer, Anne
PY - 2023/11/29
Y1 - 2023/11/29
N2 - Objective: To describe the long term risk of cervical cancer in women with untreated (that is, undergoing active surveillance) or immediately treated cervical intraepithelial neoplasia grade 2 (CIN2). Design: Nationwide population based historical cohort study. Setting: Danish healthcare registries. Participants: Women with CIN2 diagnosed in 1998-2020 and aged 18-40 years at diagnosis, who had either active surveillance or immediate treatment with large loop excision of the transformation zone (LLETZ). Women with a previous record of CIN2 or worse or LLETZ were excluded. Main outcome measure: A Weibull survival model for interval censored time-to-event data was used to estimate the cumulative risk of cervical cancer. Inverse probability treatment weighting was used to adjust estimates for age, index cytology, calendar year, and region of residence. Results: The cohort included 27 524 women with CIN2, of whom 12 483 (45%) had active surveillance and 15 041 (55%) had immediate LLETZ. During follow-up, 104 cases of cervical cancer were identified - 56 (54%) in the active surveillance group and 48 (46%) in the LLETZ group. The cumulative risk of cervical cancer was comparable across the two groups during the active surveillance period of two years. Thereafter, the risk increased in the active surveillance group, reaching 2.65% (95% confidence interval 2.07% to 3.23%) after 20 years, whereas it remained stable in the LLETZ group at 0.76% (0.58% to 0.95%). Conclusions: Undergoing active surveillance for CIN2, thereby leaving the lesion untreated, was associated with increased long term risk of cervical cancer compared with immediate LLETZ. These findings show the importance of continued follow-up of women having active surveillance.
AB - Objective: To describe the long term risk of cervical cancer in women with untreated (that is, undergoing active surveillance) or immediately treated cervical intraepithelial neoplasia grade 2 (CIN2). Design: Nationwide population based historical cohort study. Setting: Danish healthcare registries. Participants: Women with CIN2 diagnosed in 1998-2020 and aged 18-40 years at diagnosis, who had either active surveillance or immediate treatment with large loop excision of the transformation zone (LLETZ). Women with a previous record of CIN2 or worse or LLETZ were excluded. Main outcome measure: A Weibull survival model for interval censored time-to-event data was used to estimate the cumulative risk of cervical cancer. Inverse probability treatment weighting was used to adjust estimates for age, index cytology, calendar year, and region of residence. Results: The cohort included 27 524 women with CIN2, of whom 12 483 (45%) had active surveillance and 15 041 (55%) had immediate LLETZ. During follow-up, 104 cases of cervical cancer were identified - 56 (54%) in the active surveillance group and 48 (46%) in the LLETZ group. The cumulative risk of cervical cancer was comparable across the two groups during the active surveillance period of two years. Thereafter, the risk increased in the active surveillance group, reaching 2.65% (95% confidence interval 2.07% to 3.23%) after 20 years, whereas it remained stable in the LLETZ group at 0.76% (0.58% to 0.95%). Conclusions: Undergoing active surveillance for CIN2, thereby leaving the lesion untreated, was associated with increased long term risk of cervical cancer compared with immediate LLETZ. These findings show the importance of continued follow-up of women having active surveillance.
KW - Cohort Studies
KW - Colposcopy
KW - Female
KW - Humans
KW - Papillomavirus Infections/diagnosis
KW - Pregnancy
KW - Uterine Cervical Dysplasia/pathology
KW - Uterine Cervical Neoplasms/epidemiology
U2 - 10.1136/bmj-2023-075925
DO - 10.1136/bmj-2023-075925
M3 - Journal article
C2 - 38030154
AN - SCOPUS:85178649553
SN - 0959-8146
VL - 383
JO - The BMJ
JF - The BMJ
M1 - e075925
ER -